Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

NCT01877811 | Completed Phase 1

• 1 other identifier: RXDX-105-01
• Study Type: interventional
• Target: 143
• Locations: 1 country
• Sites: 14

Brief Summary

This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.

Conditions

Solid Tumors

Keywords

Lung Cancer; RET Inhibitor; Solid Tumors; RET mutations or rearrangements; BRAF mutations or rearrangements; Squamous NSCLC; KRAS mutation; Other Lung adenocarcinomas

Outcome Measures

Primary Outcomes (3)

• Phase 1: Dose Limiting Toxicities

  From signing of the informed consent up to approximately 12 months

  Approximately 12 months

• Phase 1: Occurrence of Adverse Events

  From signing of the informed consent up to approximately 12 months

  Approximately 12 months

• Phase 1b: Occurrence of Adverse Events

  To further assess the safety profile and tolerability of RXDX-105 at the RP2D

  Approximately 12 months

Secondary Outcomes (11)

• Phase 1: Maximum observed plasma drug concentration (Cmax)

  Day 1 to Day 16

• Phase 1: Time of maximum observed plasma drug concentration (tmax)

  Day 1 to Day 16

• Phase 1: Area under the plasma drug concentration versus time curve from time 0 to infinity (AUC0-∞)

  Day 1 to Day 16

• Phase 1: Area under the plasma drug concentration versus time curve from time 0 to the last measureable drug concentration (AUC0-t)

  Day 1 to Day 16

• Phase 1: Area under the plasma drug concentration versus time curve from time 0 to 24 hours after study drug administration (AUC0-24)

  Day 1 to Day 16

Study Arms (1)

RXDX-105

EXPERIMENTAL

Drug: RXDX-105

Interventions

RXDX-105 DRUG

During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day. During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.

Also known as: CEP-32496, AC013773

RXDX-105

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically or cytologically confirmed advanced solid tumors with a histology and/or molecular alteration of interest as defined in Section 4, detected by a CLIA-certified or equivalently accredited diagnostic laboratory
• Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) patients must have archival tissue available for analysis by Ignyta; all other patients must send tissue to Ignyta, if tissue is available
• Prior Treatment:
• Patients with BRAF V600E mutations must be TKI-naïve; any number of other prior therapies are allowed
• NSCLC patients with RET alterations who have had a prior RET inhibitor or are RET inhibitor-naïve will be enrolled; (any number of other prior therapies are allowed); all other histologies with RET alterations must be RET inhibitor-naïve
• Patients with Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) may have had prior TKIs and any number of other prior therapies
• Measurable disease according to RECIST v1.1 for all patients except patients with RET altered tumors; patients with RET altered tumors must have evaluable disease, but are not required to have measurable disease
• Patients with treated, stable CNS metastases, including leptomeningeal carcinomatosis are allowed. The use of seizure prophylaxis is allowed. Patients requiring steroids must be at a stable or decreasing dose for at least 2 weeks prior to the start of RXDX-105 treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Able to ingest oral medication

You may not qualify if:

• Treated with systemic anticancer therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment (4 weeks for antibody therapy and immunotherapy, and 2 weeks for bevacizumab in colon cancer patients)
• Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects of such therapy
• Radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities
• History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval \> 500 milliseconds from ECGs performed at least 24 hours apart)
• Major active infection requiring parenteral antibiotics
• Severe or unstable medical condition, such as congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (≥ Grade 2, according to NCI CTCAE v4.03), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy
• History of other previous cancer that would interfere with the determination of safety or efficacy of RXDX-105 with respect to the qualifying solid tumor malignancy
• Known infection with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C
• Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable
• Presence of a significant gastrointestinal disorder that, in the opinion of the Investigator or Sponsor, could interfere with absorption of RXDX-105 (e.g., malabsorption syndrome, gastrointestinal surgery)
• Known hypersensitivity to any of the components of RXDX-105

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (14)

City of Hope

Duarte, California, United States

Location

University of California Irvine College of Medicine

Irvine, California, United States

Location

University of California San Diego Moores Cancer Center

San Diego, California, United States

Location

Lombardi Comprehensive Cancer Center, Georgetown

Washington D.C., District of Columbia, United States

Location

Florida Cancer Center

Sarasota, Florida, United States

Location

University Cancer & Blood Center, LLC

Athens, Georgia, United States

Location

Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute

Boston, Massachusetts, United States

Location

Henry Ford Health System

Detroit, Michigan, United States

Location

Karmanos Cancer Center

Detroit, Michigan, United States

Location

Washington University

St Louis, Missouri, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Location

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Location

University of Washington, Seattle Cancer Care Alliance

Seattle, Washington, United States

Location

Related Publications (1)

• Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.

  PMID: 29538669 DERIVED

MeSH Terms

Conditions

Lung Neoplasms

Interventions

agerafenib

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2013
• First Posted: June 14, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2018
• Study Completion: February 1, 2019
• Last Updated: April 25, 2019

Record last verified: 2019-04

Locations

US (14)